Advertisement

Enzymological Aspects of the Actions of the Parkinsonism-Inducing Neurotoxin MPTP

  • James P. Sullivan
  • John M. McCrodden
  • Keith F. Tipton
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)

Abstract

The role of the B-form of monoamine oxidase (MAO-B) in converting the compound MPTP (1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) to neurotoxic metabolites is well-established from studies on the protection afforded by selective inhibitors of that enzyme (for reviews see Singer et al., 1987; Kinemuchi et al., 1987). The neurotoxic metabolite appears to be the 4-electron oxidation product, the 4-phenylpyridinium ion (MPP(+)). It has been proposed that the action of this compound as an inhibitor of mitochondrial oxidative phosphorylation from NADH may account for its neurotoxicity (Nicklas et al., 1985; Ramsay et al., 1986).

Keywords

Monoamine Oxidase Brain Mitochondrion Mitochondrial Oxidative Phosphorylation Partition Ratio Deuterium Isotope Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Corongiu, F.P., Dessi, M.A., Banni, S., Bernardi, F., Piccardi, M.P. Del Zompo, M. and Corsini, G.U., 1987, MPTP fails to induce lipid peroxidation in vivo, Biochem. Pharmacol., 36: 2551.CrossRefGoogle Scholar
  2. Fowler, C.J. and Strolin Benedetti, M., 1983, The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by címoxatone, J. Neurochem. 40: 1534.PubMedCrossRefGoogle Scholar
  3. Fowler, C.J., Wiberg, A., Oreland, L., Marcusson, J. and Winblad, B., 1980, The effects of age on the activity and molecular properties of human brain monoamine oxidase, J. Neural Transm. 49: 1.PubMedCrossRefGoogle Scholar
  4. Gotz, M.E., Freyberger, A. and Riederer, P., 1989, Oxidative stress: a role in the pathogenesis of Parkinson’s disease, J. Neural Transm., in press.Google Scholar
  5. Irwin, I.J., Langston, W.L. and Delanney, L.E., 1987, 5-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP(+) concentration and neurotoxicity, Life Sci, 40: 731.CrossRefGoogle Scholar
  6. Jenner, P. and Marsden, C.D., 1986, The actions of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine in animals as models of Parkinson’s disease, J. Neural Transm., suppl. 20: 11.Google Scholar
  7. Kinemuchi, H., Fowler, C.J. and Tipton, K.F., 1987, The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson’s disease, Neurochem. Int., 11: 359.PubMedCrossRefGoogle Scholar
  8. Nicklas, W.J., Vyas, I. and Heikkila, R.E., 1985, Inhibition of NAD-linked oxidation in human brain mitochondria by 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine, Life Sci, 36: 2503.PubMedCrossRefGoogle Scholar
  9. O’Carroll, A.-M., Tipton„ K.F., Sullivan, J.P., Fowler, C.J. and Ross, S.B., 1987, Intra-and extra-synaptosomal deamination of dopamine and noradrenaline by the two forms of human brain monoamine oxidase, implications for the neurotoxicity of N-methyl-4-phenyl-1,2,3,6tetrahydropyridine in man, Biogenic Aamines, 4: 165.Google Scholar
  10. Ottoboni, S., Caldera, P., Trevor, A. and Castagnoli, N., 1989, Deuterium isotope effect measurements on the interactions of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidase B, J. Biol. Chem., 264: 13684.PubMedGoogle Scholar
  11. Ramsay, R.R., Dadgar, J.I., Trevor, A. and Singer, T.P., 1986, Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity, Life Sci, 39: 581.PubMedCrossRefGoogle Scholar
  12. Salachi, J.I., 1979, Monoamine oxidase from beef liver mitochondria: simplified isolation procedure, properties and determination of its cysteinyl flavin content, Arch. Biochem. Biophys, 192: 128.CrossRefGoogle Scholar
  13. Singer, T.P., Castagnoli, N., Ramsay, R.R. and Trevor, A.J., 1987, Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, J. Neurochem., 49: 1.PubMedCrossRefGoogle Scholar
  14. Snyder, S.H. and D’Amato, R.J., 1985, Predicting Parkinson’s disease, Nature, 317: 198.PubMedCrossRefGoogle Scholar
  15. Sullivan, J.P. and Tipton, K.F., 1988, Interactions of monoamine oxidase and MPTP in human brain, In “Neurotoxins in Neurochemistry”, J.0. Dolly, ed, Ellis Horwood, Chichester, p. 125.Google Scholar
  16. Thorpe, L.W., Westlund, K.N., Kochersperger, L.M., Abell, C.W. and Denney, R.M., 1987, Immunocytochemical localisation of monoamine oxidase A and B in human peripheral tissue and brain, J. Histochem. Cytochem., 35: 23.PubMedCrossRefGoogle Scholar
  17. Tipton, K.F., McCrodden, J.M. and Youdim, M.B.H., 1986, Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Biochem. J., 125–521.Google Scholar
  18. Tipton, K.F. and Sullivan, J.P., 1989, Biochemical aspects of the neuro-toxicity of 1-methy1–4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Roy. Irish Acad., in press.Google Scholar
  19. Trevor, A.J., Chiba, K., Yu, E.Y., Caldera, P.S., Castagnoli, K.P., Castagboli, N., Peterson, L., Salach, J.I. and Singer, T.P., 1986, in: “MPTP: A neurotoxin producing a parkinsonian syndrome”, S.P. Markey, N. Castagnoli, A.J. Trevor and I.K. Kopin, eds., Academic Press, New York, p. 161.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • James P. Sullivan
    • 1
  • John M. McCrodden
    • 1
  • Keith F. Tipton
    • 1
  1. 1.Department of BiochemistryTrinity CollegeDublin 2Ireland

Personalised recommendations